<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675750</url>
  </required_header>
  <id_info>
    <org_study_id>201740089</org_study_id>
    <nct_id>NCT03675750</nct_id>
  </id_info>
  <brief_title>Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism</brief_title>
  <official_title>Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic
      drugs and the effects of the duration of hyperprolactinemia on bone metabolism in
      schizophrenia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperprolactinemia is a common adverse effect of antipsychotic drugs. Studies have shown that
      hyperprolactinemia may affect bone metabolism through direct and indirect effects and
      increase the risk of osteoporosis and fracture.The investigators assess the duration, the
      severity of hyperprolactinemia and its effects on bone metabolism in schizophrenics taking
      antipsychotic drugs through analyzing the correlation between prolactin levels and
      biochemical markers of bone metabolism and the correlation between the duration of
      hyperprolactinemia and abnormal bone metabolism. Meanwhile, the investigators aims to obtain
      the boundary value of prolactin levels in patients with abnormal bone metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone turnover biochemical markers</measure>
    <time_frame>baseline ,4 weeks ,8 weeks，12 weeks and 26 weeks</time_frame>
    <description>changes in the level of serum bone alkaline phosphatase ,serum β-crosslaps and from baseline to 4, 8, 12 and 26 weeks after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum prolactin</measure>
    <time_frame>baseline ,4 weeks ,8 weeks，12 weeks and 26 weeks</time_frame>
    <description>changes in the level of serum prolactin from baseline to 4, 8, 12 and 26 weeks after enrollment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum bone alkaline phosphatase ,serum β-crosslaps and prolactin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese outpatients or inpatients with schizophrenia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Diagnosis of the disease meets the ICD-10 diagnostic criteria for schizophrenia 2.
             Subjects Intend to use atypical antipsychotics 3. Age between 18 and 50 years of age

        Exclusion Criteria:

          -  1. Pregnant and breast feeding women 2. Abnormal lipid metabolism 3. The level of
             serum alanine aminotransferase or aspartate aminotransferase is two times higher than
             the upper limit of the normal 4. Patients with diabetes or impaired fasting glucose 5.
             The level of prolactin is higher than normal 6. Patients taking drugs that affect bone
             metabolism (e.g. selective serotonin reuptake inhibitors antidepressants,
             antiepileptic drugs) 7. The level of creatinine is 1.2 times higher than the upper
             limit of the normal value
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LiHua Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LiHua Wang</last_name>
    <phone>18017311510</phone>
    <email>ashleyzhima@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LiHua Wang</last_name>
      <phone>18017311510</phone>
      <email>ashleyzhima@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antipsychotic drugs</keyword>
  <keyword>hyperprolactinemia</keyword>
  <keyword>bone metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

